SINGAPORE, Jan 4 (Bernama-GLOBE NEWSWIRE) —Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced today that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell (EBVST) therapy platform, while seeking strategic options for the development of its TT11 autologous CAR-T platform with other companies.
The decision to prioritize the allogeneic or “off-the-shelf-approach” over the autologous platform followed progress and new data with its TT11X clinical program, including strong safety and efficacy data presented in an oral podium presentation at the 64th Annual Meeting of the American Society of Hematology (ASH). The data demonstrated TT11X to be well-tolerated at all dosing levels, eliciting a 79% overall response rate and 43% complete response rate among 14 heavily pre-treated CD30-positve Hodgkin lymphoma patients.
